π«β‘CRT has transformed HF care, but nonresponse is common.
Key challenges:
β’ Pt selection & conduction disease characterizationπ―
β’ Device programmingβοΈ
β’ Delayed referralβ±οΈ & equity gapsπ€
Conduction-system pacing may be the future
π https://bit.ly/3MqLfaD
π«#THTSimPub Alert
This π₯State-of-the-Art Review examines HeartLogic, a multisensor algorithm embedded in existing CIEDs to detect early HF decompensation, as well as the DANLOGIC-HF RCT which will test whether guided management reduces HF events!
π https://bit.ly/46D91Hv
π«#THT2026 Sim Pub Alertπ¨: A medically-trained LLM #AI model integrated within a health system EMR accurately screened pts for a rare ATTR-CM trial, providing eligibility justifications & improving diversity vs routine workflows.
π https://bit.ly/4u8aAar
π«π¨ #THTSimPub Alert!
β
In >25K HF pts, higher GDMT scores were linked to β¬οΈ mortality & hospitalization across EF, including HFmrEF & HFpEF.
β
ARNI showed benefit vs ACEi/ARB across EF groups.
β
Time to rethink GDMT in non-HFrEF populations?
π https://bit.ly/3PftpII
#THTSimPub
As DCD π« transplant grows, ethical, regulatory & oversight questions are intensifying.
A Perspectives piece from @MaryjaneFarrMD examines policy shifts, AST/ASTS guidance, & whether a pause on DCD is warranted as the transplant system evolves.
π https://bit.ly/4lcknIz
π«#THTSimPub
In INOCA pts undergoing IMR + exercise hemodynamics, higher IMR (chronic microvasc dysfx) was linked to early HFpEF physiology:
β¬οΈexercise RAP & PCWP
β¬οΈ PCWL
β¬οΈ prevalent ΞmPAP/ΞCO slope >3.
CMD may be an upstream driver of HFpEF.
π https://bit.ly/4cmsH6d
π¨ #THT2026 SimPub: In a post-hoc DanGer Shock analysis, CS phenotypes showed distinct outcomes: 180-day mortality 33% (non-congested), 47% (cardiorenal), 69% (cardiometabolic). mAFP benefit appeared greatest in non-congested CS. Phenotype-guided shock care?
π https://bit.ly/407Blya
#THTSimPub
A new JCF Ignite! highlights compelling ΒΉβ΄C birth-dating research: cardiomyocyte renewal is suppressed in advanced HF, but increases in pts who recover after LVAD support.π«βοΈ
A biologic signal that unloading may enable myocardial recovery.
π https://bit.ly/4coPnTg
π«π§¬#THTSimPub
A Perspectives by Dr. Douglas Mann proposes the cardio-hematopoietic axis as a unifying framework for HFpEF, linking systemic inflammation & immunity, microvascular dysfunction & fibrosis. Time to view HFpEF as a systemic immuneβcardiac disorder.
π https://bit.ly/3OFpJzX
#THTSimPub
In cardiogenic shock pts on tMCS, blood pressure response index showed the strongest prognostic accuracy for mortality & native π« survival. Each 10-pt β¬οΈ β 46% β¬οΈ mortality, consistent across Impella & IABP.
A potential key hemodynamic metric.
π https://bit.ly/4simDjN
In a Brief Report this month, investigators compared tirzepatide (GIP/GLP-1) vs semaglutide (GLP-1) in pts with HFpEF + T2DM.π
No significant differences were seen in HF decompensations, mortality, hospitalizations, or adverse events between groups.
π https://bit.ly/4qPptMd
The next chapter of heart transplantation is being written now. Submit to JCFβs Focus Issue on Innovations in Heart Transplantation. π«
Submissions due by April 10, 2026.
#CallForPapers #HeartTransplantation #Cardiology
π£ Now accepting submissions for our upcoming Focus Issue:
Artificial Intelligence and Heart Failure: A Critical Juncture
As AI reshapes cardiovascular care, this issue will examine its promise, limitations, and clinical impact.
ποΈ Submit by May 10, 2026
https://bit.ly/4kJl5gf
#AIinHealthcare
Check out the latest Brief Report -- 96-week efficacy & safety data from FOREST-HCM: Aficamten in non-obstructive HCMπ₯
β
Sustained improvements in functional status
β
Low cardiac biomarker levels
β
Minimal low-EF adverse events
π https://bit.ly/3OhMIRd
Whatβs shaping heart failure research right now? Find out in this month's issue of the Journal of Cardiac Failure π«
Start reading π https://onlinejcf.com/current
#HeartFailure #Cardiology
From evolving transplant techniques to post-transplant management and outcomes, JCFβs upcoming Focus Issue will explore Innovations in Heart Transplantation.
π Submit your research by April 10, 2026.
#CallForPapers #HeartTransplantation #Cardiology
π¨ICYMI! A joint scientific statement from @HFSA and @ASPCardio, reframes #HeartFailure as a lifespan prevention challenge, from primary prevention to advanced HF care. It provides a conceptual roadmap along which to consider all aspects of preventive care
π https://bit.ly/49dXlN1
In the accompanying π₯editorial, the authors parse the existing data on PA sensors, including the conclusions of this analysis of PROACTIVE-HF.
They opine: "PA sensors are positioned to transform the lived experience of patients with heart failure."
π bit.ly/4pHpLUQ
In this analysis, ambulatory hemodynamic monitoring using seated mPAP, loop diuretic up-titration lowered mPAP within days, while down-titration raised it. ARNI and MRA changes showed variable effects. Real-time hemodynamics may help guide HF med titration!
π bit.ly/4qNO1W5
π£ JCF is now accepting submissions for a Focus Issue dedicated to Innovations in Heart Transplantation, highlighting advances across clinical practice, research, and patient outcomes.
ποΈ Deadline to submit: April 10, 2026
#CallForPapers #HeartTransplantation #Cardiology
Integrated health tech in HF faces real challenges: access gapsπ±, privacy/securityπ, workflow disruptionsβοΈ & costs πΈ. A new SS from @HFSA & @AAHFN highlights solutions: better engagement, interoperability, reimbursement & future directions like automation & ML
π bit.ly/3Z5bgzb
New scientific statement from @hfsa.bsky.social & AAHFN! Integrated health technologies are reshaping HF careπ», from telemonitoring to mobile apps to implantables. Benefits include β¬οΈQoL & β¬οΈhospitalizations, but success depends on many complex factors.
π bit.ly/3Z5bgzb
Todayβs AHF pts are older, obese & multimorbid w/βinflammagingβ rather than just pump failure. The latest SotA Review suggests early initiation of 4 GDMT pillars during AHFβand possibly added anti-inflammatory therapyβmay improve longer-term outcomes & remission.
π https://bit.ly/3Z2S5Wx
A New Year brings new insights.
The January issue of JCF is here, highlighting timely research and emerging conversations shaping the year ahead in heart failure science.
Start reading π https://onlinejcf.com/current
#HeartFailure #Cardiology
New science π¨! In the BRING-UP-3 HF study, among ambulatory HF pts in Italy, 65% of HFrEF pt received all 4 GDMT pillars. BBs & RASi/ARNI >90%, MRAs & SGLT2i >80% (though target doses still low). SGLT2i already common in HFmrEF (72%) & HFpEF (50%)!
π https://bit.ly/44jVymK
Despite strong evidence, GDMT remains underused. In this Indian expert consensus doc, using a modified Delphi process, authors propose simplified, patient-profileβbased guidance to enable early, safe initiation of the 4 GDMT pillars & improve outcomes in HFrEF.
π bit.ly/4iZB48Q
Tricuspid regurgitation in β€οΈβπ©Ή HFpEF isnβt benignπ‘
In 206 pts undergoing invasive exercise testing π΄ββοΈ, moderateβsevere TR (vs absent-mild) was linked to ...
β¬οΈ cardiac reserve β lower peak CO, higher mPAPβCO slope
3.3Γ higher 5-yr composite HFH or death.
π https://bit.ly/4hZ3YWl
π Donβt miss the accompanying editorial!
It dives deeper into this #HeartFailure study β exploring:
π Diverse etiologies of high-output HF (HOHF)
π How these findings challenge conventional wisdom
π Practical implications for clinical care
π bit.ly/47CV8Kf
π¨ High-output heart failure (HOHF): when more isnβt better!
π€ Which hemodynamic parameter best predicts outcomes in HOHF?
π PCWP, PAPi & PAP β not independently linked to mortality
π‘ Elevated cardiac index (CI) = strongest predictor of all-cause mortality.
π bit.ly/47EZC3b
π Can provocative testing during RHC unmask HFpEF?
PAWP withπ¦΅passive leg raise & π΄ββοΈlow-workload exercise help narrow the diagnostic gray zone.
π§ Great for ruling in HFpEF β less reliable for ruling it out!
#Hemodynamics #HFpEF
π https://bit.ly/4oxDZro
